Director/PDMR Shareholding

RNS Number : 7388T

GlaxoSmithKline PLC

16 October 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 75.595 (personal contribution) £15.275 187.204 (personal contribution) £15.275 203.821 (personal contribution) £15.275 75.595 (personal contribution) £15.275 187.191 (personal contribution) £15.275 203.809 (personal contribution) £15.275 75.595 (matching shares) £15.275 187.204 (matching shares) £15.275 203.821 (matching shares) £15.275 75.595 (matching shares) £15.275 187.191 (matching shares) £15.275 203.809 (matching shares)
d)	Aggregated information Aggregated volume Price	1,866.43 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 55.361 (personal contribution) £15.275 127.190 (personal contribution) £15.275 106.128 (personal contribution) £15.275 55.361 (personal contribution) £15.275 106.115 (personal contribution) £15.275 55.361 (matching shares) £15.275 127.19 (matching shares) £15.275 106.128 (matching shares) £15.275 55.361 (matching shares) £15.275 106.115 (matching contribution)
d)	Aggregated information Aggregated volume Price	900.310 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Debruyne
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 178.377 (personal contribution) £15.275 178.365 (personal contribution) £15.275 178.377 (matching shares) £15.275 178.365 (matching shares)
d)	Aggregated information Aggregated volume Price	713.484 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 105.590 (personal contribution) £15.275 247.218 (personal contribution) £15.275 185.166 (personal contribution) £15.275 105.576 (personal contribution) £15.275 247.205 (personal contribution) £15.275 185.166 (personal contribution) £15.275 105.590 (matching shares) £15.275 247.218 (matching shares) £15.275 185.166 (matching shares) £15.275 105.576 (matching shares) £15.275 247.205 (matching shares) £15.275 185.166 (matching shares)
d)	Aggregated information Aggregated volume Price	2,151.842 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 38.762 (personal contribution) £15.275 91.407 (personal contribution) £15.275 67.081 (personal contribution) £15.275 38.762 (personal contribution) £15.275 91.407 (personal contribution) £15.275 67.068 (personal contribution) £15.275 38.762 (matching shares) £15.275 91.407 (matching shares) £15.275 67.081 (matching shares) £15.275 38.762 (matching shares) £15.275 91.407 (matching shares) £15.275 67.068 (matching shares)
d)	Aggregated information Aggregated volume Price	788.974 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.020 75.963 (personal contribution) $41.020 75.963 (matching shares)
d)	Aggregated information Aggregated volume Price	151.926 $41.020
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 62.115 (personal contribution) £15.275 116.331 (personal contribution) £15.275 84.422 (personal contribution) £15.275 62.115 (personal contribution) £15.275 116.331 (personal contribution) £15.275 84.409 (personal contribution) £15.275 62.115 (matching shares) £15.275 116.331 (matching shares) £15.275 84.422 (matching shares) £15.275 62.115 (matching shares) £15.275 116.331 (matching shares) £15.275 84.409 (matching shares)
d)	Aggregated information Aggregated volume Price	1,051.446 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 83.607 (personal contribution) £15.275 170.189 (personal contribution) £15.275 127.067 (personal contribution) £15.275 83.594 (personal contribution) £15.275 170.189 (personal contribution) £15.275 127.067 (personal contribution) £15.275 83.607 (matching shares) £15.275 170.189 (matching shares) £15.275 127.067 (matching shares) £15.275 83.594 (matching shares) £15.275 170.189 (matching shares) £15.275 127.067 (matching shares)
d)	Aggregated information Aggregated volume Price	1,523.426 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 56.787 (personal contribution) £15.275 104.127 (personal contribution) £15.275 79.994 (personal contribution) £15.275 56.787 (matching shares) £15.275 104.127 (matching shares) £15.275 79.994 (matching shares)
d)	Aggregated information Aggregated volume Price	481.816 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.020 43.227 (personal contribution) $41.020 97.329 (personal contribution) $41.020 80.611 (personal contribution) $41.020 43.227 (personal contribution) $41.020 97.329 (personal contribution) $41.020 80.599 (personal contribution) $41.020 43.227 (matching shares) $41.020 97.329 (matching shares) $41.020 80.611 (matching shares) $41.020 43.227 (matching shares) $41.020 97.329 (matching shares) $41.020 80.599 (matching shares)
d)	Aggregated information Aggregated volume Price	884.644 $41.020
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.275 123.070 (personal contribution) £15.275 200.197 (personal contribution) £15.275 138.016 (personal contribution) £15.275 123.070 (personal contribution) £15.275 200.197 (personal contribution) £15.275 138.016 (personal contribution) £15.275 123.070 (matching shares) £15.275 200.197 (matching shares) £15.275 138.016 (matching shares) £15.275 123.070 (matching shares) £15.275 200.197 (matching shares) £15.275 138.016 (matching shares)
d)	Aggregated information Aggregated volume Price	1,845.132 £15.275
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

 

END

 

 

DSHEQLFFDBFEFBF